Advertisement

Topics

Heplisav-B Approval Has Dynavax Going It Alone On US Launch In Early 2018

12:51 EST 13 Nov 2017 | SCRIP

Hepatitis B vaccine's favorable efficacy data relative to GSK's Engerix-B and neutral safety language mean that any partnership opportunity 'would...

      

Related Stories

 

Original Article: Heplisav-B Approval Has Dynavax Going It Alone On US Launch In Early 2018

NEXT ARTICLE

More From BioPortfolio on "Heplisav-B Approval Has Dynavax Going It Alone On US Launch In Early 2018"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...